NCT04683315View on ClinicalTrials.gov

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

PHASE2RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

mFOLFIRINOX Treatment Regimen

This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).

DRUG

Gemcitabine/Nab-paclitaxel Treatment Regimen

This regimen will be nab-paclitaxel and gemcitabine.

RADIATION

Chemoradiation

50.4 Gy in 28 fractions.

Trial Locations (2)

53226

RECRUITING

Froedtert & the Medical College of Wisconsin, Milwaukee

85258-4566

RECRUITING

HonorHealth Medical Group, Scottsdale

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER